Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Free Cash Flow (2019 - 2025)

Historic Free Cash Flow for Beam Therapeutics (BEAM) over the last 7 years, with Q3 2025 value amounting to -$86.5 million.

  • Beam Therapeutics' Free Cash Flow rose 358.07% to -$86.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$352.4 million, marking a year-over-year decrease of 14238.34%. This contributed to the annual value of -$356.2 million for FY2024, which is 9471.81% down from last year.
  • Per Beam Therapeutics' latest filing, its Free Cash Flow stood at -$86.5 million for Q3 2025, which was up 358.07% from -$79.6 million recorded in Q2 2025.
  • Beam Therapeutics' 5-year Free Cash Flow high stood at $203.2 million for Q1 2022, and its period low was -$120.5 million during Q1 2023.
  • In the last 5 years, Beam Therapeutics' Free Cash Flow had a median value of -$79.6 million in 2025 and averaged -$50.1 million.
  • Examining YoY changes over the last 5 years, Beam Therapeutics' Free Cash Flow showed a top increase of 50591.34% in 2022 and a maximum decrease of 301153.98% in 2022.
  • Beam Therapeutics' Free Cash Flow (Quarter) stood at -$11.5 million in 2021, then plummeted by 571.22% to -$77.5 million in 2022, then skyrocketed by 269.76% to $131.5 million in 2023, then crashed by 160.34% to -$79.3 million in 2024, then fell by 9.02% to -$86.5 million in 2025.
  • Its Free Cash Flow stands at -$86.5 million for Q3 2025, versus -$79.6 million for Q2 2025 and -$106.9 million for Q1 2025.